Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.

Landais E, Murrell B, Briney B, Murrell S, Rantalainen K, Berndsen ZT, Ramos A, Wickramasinghe L, Smith ML, Eren K, de Val N, Wu M, Cappelletti A, Umotoy J, Lie Y, Wrin T, Algate P, Chan-Hui PY, Karita E; IAVI Protocol C Investigators; IAVI African HIV Research Network, Ward AB, Wilson IA, Burton DR, Smith D, Pond SLK, Poignard P.

Immunity. 2017 Nov 21;47(5):990-1003.e9. doi: 10.1016/j.immuni.2017.11.002.

2.

Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.

Pincus SH, Song K, Maresh GA, Hamer DH, Dimitrov DS, Chen W, Zhang MY, Ghetie VF, Chan-Hui PY, Robinson JE, Vitetta ES.

J Virol. 2017 Jan 18;91(3). pii: e01955-16. doi: 10.1128/JVI.01955-16. Print 2017 Feb 1.

3.

Immunological considerations for developing antibody therapeutics for Influenza A.

Chan-Hui PY, Swiderek KM.

Hum Vaccin Immunother. 2016;12(2):474-7. doi: 10.1080/21645515.2015.1079676.

4.

Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice.

Stoddart CA, Galkina SA, Joshi P, Kosikova G, Long BR, Maidji E, Moreno ME, Rivera JM, Sanford UR, Sloan B, Cieplak W, Wrin T, Chan-Hui PY.

Virology. 2014 Aug;462-463:115-25. doi: 10.1016/j.virol.2014.05.036. Epub 2014 Jun 25.

5.

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.

Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang CH, Mcbride R, von Bredow B, Shivatare SS, Wu CY, Chan-Hui PY, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, Swiderek K, Moore JP, Evans D, Paulson JC, Wong CH, Ward AB, Wilson IA, Sanders RW, Poignard P, Burton DR.

Immunity. 2014 May 15;40(5):657-68. doi: 10.1016/j.immuni.2014.04.009. Epub 2014 Apr 24.

6.

The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies.

Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien JP, Briney B, Ramos A, Saye KF, Le K, Mahan A, Wang S, Kardar M, Yaari G, Walker LM, Simen BB, St John EP, Chan-Hui PY, Swiderek K, Kleinstein SH, Alter G, Seaman MS, Chakraborty AK, Koller D, Wilson IA, Church GM, Burton DR, Poignard P.

PLoS Pathog. 2013;9(11):e1003754. doi: 10.1371/journal.ppat.1003754. Epub 2013 Nov 21. Erratum in: PLoS Pathog. 2013 Dec;9(12). doi:10.1371/annotation/f1f8c791-61e9-45c6-a455-92c6dadf9f06. Kleinstein, Stephen H [corrected to Kleinstein, Steven H].

7.

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.

Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P, Burton DR.

Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18921-5. doi: 10.1073/pnas.1214785109. Epub 2012 Oct 25.

8.

Broad neutralization coverage of HIV by multiple highly potent antibodies.

Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD; Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P.

Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.

9.

Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses.

Grandea AG 3rd, Olsen OA, Cox TC, Renshaw M, Hammond PW, Chan-Hui PY, Mitcham JL, Cieplak W, Stewart SM, Grantham ML, Pekosz A, Kiso M, Shinya K, Hatta M, Kawaoka Y, Moyle M.

Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12658-63. doi: 10.1073/pnas.0911806107. Epub 2010 Jul 1.

10.

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW; Protocol G Principal Investigators, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR.

Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3.

11.

Applications of eTag trade mark assay platform to systems biology approaches in molecular oncology and toxicology studies.

Chan-Hui PY, Stephens K, Warnock RA, Singh S.

Clin Immunol. 2004 May;111(2):162-74. Review.

PMID:
15137949
12.

From PGx to molecular diagnostics and personalized medicine.

Chan-Hui PY.

Drug Discov Today. 2003 Sep 15;8(18):829-31. No abstract available.

PMID:
12963318
14.

Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase.

Wang XS, Diener K, Manthey CL, Wang S, Rosenzweig B, Bray J, Delaney J, Cole CN, Chan-Hui PY, Mantlo N, Lichenstein HS, Zukowski M, Yao Z.

J Biol Chem. 1997 Sep 19;272(38):23668-74.

15.

Kinase suppressor of Ras is ceramide-activated protein kinase.

Zhang Y, Yao B, Delikat S, Bayoumy S, Lin XH, Basu S, McGinley M, Chan-Hui PY, Lichenstein H, Kolesnick R.

Cell. 1997 Apr 4;89(1):63-72.

16.

Control of adhesion-dependent cell survival by focal adhesion kinase.

Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY.

J Cell Biol. 1996 Aug;134(3):793-9.

Supplemental Content

Loading ...
Support Center